Mobia Medical Maintains Vivistim Procedure Payment Code
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: Newsfilter
- Payment Code Maintenance: CMS has proposed to maintain CPT Code 64568 for the Vivistim procedure in 2027, with an outpatient payment rate of approximately $45,000, unchanged from 2026, providing financial stability for hospitals to expand their Vivistim programs.
- Market Adoption Support: CEO Richard Foust stated that the continuity of the payment code will enhance hospitals' confidence in the Vivistim technology, thereby broadening access for Medicare beneficiaries and driving further market adoption.
- Technological Innovation: The Vivistim® Paired VNS™ System is the first clinically validated, FDA-approved implantable solution designed to improve motor function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments, showcasing Mobia's technological leadership in stroke recovery.
- Forward-Looking Outlook: Mobia anticipates that CMS will publish the final OPPS rule in November, with any changes taking effect on January 1, 2027, providing a positive outlook for the company's future commercial expansion and patient access.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MOBI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MOBI
Wall Street analysts forecast MOBI stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 13.250
Low
Averages
High
Current: 13.250
Low
Averages
High
About MOBI
Mobia Medical, Inc. is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The Company’s Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System is the clinically validated, FDA-approved solution for chronic ischemic stroke survivors with moderate to severe upper extremity impairments. The Vivistim System includes an implantable device that stimulates the vagus nerve only when intentionally activated, triggering the release of neuromodulators, including acetylcholine, norepinephrine, and serotonin. Its neuromodulators create a heightened state of plasticity in the brain, such that neural networks can more readily adapt and reform in response to stimuli. The implantable components of the Vivistim System-namely, the implantable pulse generator (IPG) and lead-are implanted through a minimally invasive outpatient procedure that takes approximately 60 minutes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mobia Medical Maintains Vivistim Procedure Payment Code
- Payment Code Maintenance: CMS has proposed to maintain CPT Code 64568 for the Vivistim procedure in 2027, with an outpatient payment rate of approximately $45,000, unchanged from 2026, providing financial stability for hospitals to expand their Vivistim programs.
- Market Adoption Support: CEO Richard Foust stated that the continuity of the payment code will enhance hospitals' confidence in the Vivistim technology, thereby broadening access for Medicare beneficiaries and driving further market adoption.
- Technological Innovation: The Vivistim® Paired VNS™ System is the first clinically validated, FDA-approved implantable solution designed to improve motor function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments, showcasing Mobia's technological leadership in stroke recovery.
- Forward-Looking Outlook: Mobia anticipates that CMS will publish the final OPPS rule in November, with any changes taking effect on January 1, 2027, providing a positive outlook for the company's future commercial expansion and patient access.
See More
CervoMed and Others See Significant Stock Gains
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
See More
Latest Rating Changes on Wall Street
- TripAdvisor Upgrade: Wedbush upgraded TripAdvisor from neutral to outperform, citing the stock's undervaluation and expected governance transformation post-LTRIP merger, alongside activist involvement as catalysts for future growth.
- Knight-Swift Outlook: Susquehanna upgraded Knight-Swift from neutral to positive, highlighting strong earnings prospects in the trucking sector, although it noted that much of the good news is already priced in.
- Mobia Medical Coverage Initiation: Goldman Sachs initiated coverage on Mobia Medical with a buy rating and a $31 price target, indicating approximately 130% upside potential, reflecting the company's strong growth prospects in the medtech space.
- Intuit Downgrade: Goldman Sachs downgraded Intuit from neutral to sell, expressing concerns over heightened competition and noting a 46% year-to-date decline in stock price, which raises doubts about its future profitability.
See More
Mobia Medical Poised for Growth in Stroke Recovery Market
- Significant Market Potential: Mobia Medical's innovative neurostimulation technology is expected to serve approximately 1 million patients in the U.S., highlighting a substantial market opportunity, particularly given the high unmet need and limited competitive therapies.
- Upgraded Investment Rating: Goldman Sachs initiated coverage on Mobia Medical with a buy rating and set a price target of $31, implying a 130% upside from Monday's close of $13.50, reflecting analysts' confidence in the company's growth prospects.
- Strong IPO Performance: Mobia went public on Nasdaq on May 8 at an initial price of $15, and since then, its stock has risen about 15%, with a 9% increase on Tuesday following Goldman's bullish call, indicating market optimism about its future.
- Rising Stroke Incidence: With approximately 800,000 strokes occurring annually in the U.S., a figure expected to rise due to an aging population, Mobia's Vivistim system is poised to address the growing patient demand, further solidifying its market position.
See More
Five IPOs and Three SPACs Priced This Week
- HawkEye 360 IPO Performance: HawkEye 360 priced at the top of its range, raising $416 million with a market cap of $2.8 billion; despite being unprofitable, its strong revenue growth and increasing backlog indicate significant potential in the defense technology sector.
- Odyssey Therapeutics Financing: Odyssey Therapeutics priced its upsized IPO at the top of the range, raising $279 million with a market cap of $911 million; although its stock fell 9%, the development of targeted therapies for autoimmune diseases suggests robust market demand.
- Suja Life Market Challenges: Suja Life priced at the bottom of its range, raising $187 million with an $813 million market cap; despite leading in the cold-pressed juice market, a 15% decline in stock price highlights potential threats from shifting consumer preferences.
- Rare Earths Americas IPO Success: Rare Earths Americas priced at the top of its range, raising $63 million with a market cap of $399 million; focusing on heavy rare earth elements, its stock rose 23% during the week, reflecting market confidence in its growth prospects.
See More
Odyssey and Mobia Stocks Plummet After IPOs Raising Over $450M
- Odyssey IPO Performance: Odyssey Therapeutics (ODTX) raised approximately $304 million in its IPO, opening at $20, an 11% increase from its $18 offering price, but by 2 PM ET, the stock had declined to $16.49, reflecting an 8% pullback that raises concerns about its long-term growth potential.
- Mobia Stock Fluctuation: Mobia Medical (MOBI) raised $150 million in its IPO, opening at $14, down 7% from its $15 offering price, and further dropped to $11.49 by 2:10 PM ET, indicating a 23% decline, suggesting a lack of investor confidence in its market outlook.
- Market Reaction Analysis: Both companies experienced significant stock price declines post-IPO, indicating that despite raising over $450 million, the market remains cautious about the short-term performance of the biotech and MedTech sectors, which could impact future fundraising capabilities.
- Investor Confidence Challenge: The IPO performances of Odyssey and Mobia reflect a testing of investor confidence in newly listed companies, particularly in the current economic climate, which may lead to diminished interest in similar firms in the future.
See More
Mobia Medical Maintains Vivistim Procedure Payment Code
- Payment Code Maintenance: CMS has proposed to maintain CPT Code 64568 for the Vivistim procedure in 2027, with an outpatient payment rate of approximately $45,000, unchanged from 2026, providing financial stability for hospitals to expand their Vivistim programs.
- Market Adoption Support: CEO Richard Foust stated that the continuity of the payment code will enhance hospitals' confidence in the Vivistim technology, thereby broadening access for Medicare beneficiaries and driving further market adoption.
- Technological Innovation: The Vivistim® Paired VNS™ System is the first clinically validated, FDA-approved implantable solution designed to improve motor function in chronic ischemic stroke survivors with moderate to severe upper extremity impairments, showcasing Mobia's technological leadership in stroke recovery.
- Forward-Looking Outlook: Mobia anticipates that CMS will publish the final OPPS rule in November, with any changes taking effect on January 1, 2027, providing a positive outlook for the company's future commercial expansion and patient access.
See More
CervoMed and Others See Significant Stock Gains
- CervoMed Clinical Progress: CervoMed's lead drug candidate Neflamapimod has completed enrollment in its Phase 2a trial in the US, with 24-week biomarker data expected in Q4 2023, which will significantly bolster its market potential in treating dementia.
- Conexeu Leadership Expansion: Conexeu Sciences expanded its board from six to nine members and appointed a Chief Commercial Officer to accelerate the development of its 3D-printed bioregenerative breast matrix, aiming to enhance market execution and growth potential.
- NeOnc International Regulatory Approval: NeOnc Technologies received regulatory clearance from the Department of Health - Abu Dhabi to initiate a Phase 2 trial of NEO212 for aggressive brain tumors, marking a significant step in its international development and enhancing its competitive position.
- Simulations Plus Acquisition Agreement: Simulations Plus has agreed to be acquired by Altaris for $375 million, with shareholders set to receive $18.50 per share, representing a premium, and the transaction is expected to close in Q4 2023, providing new capital and resources for future growth.
See More
Latest Rating Changes on Wall Street
- TripAdvisor Upgrade: Wedbush upgraded TripAdvisor from neutral to outperform, citing the stock's undervaluation and expected governance transformation post-LTRIP merger, alongside activist involvement as catalysts for future growth.
- Knight-Swift Outlook: Susquehanna upgraded Knight-Swift from neutral to positive, highlighting strong earnings prospects in the trucking sector, although it noted that much of the good news is already priced in.
- Mobia Medical Coverage Initiation: Goldman Sachs initiated coverage on Mobia Medical with a buy rating and a $31 price target, indicating approximately 130% upside potential, reflecting the company's strong growth prospects in the medtech space.
- Intuit Downgrade: Goldman Sachs downgraded Intuit from neutral to sell, expressing concerns over heightened competition and noting a 46% year-to-date decline in stock price, which raises doubts about its future profitability.
See More
Mobia Medical Poised for Growth in Stroke Recovery Market
- Significant Market Potential: Mobia Medical's innovative neurostimulation technology is expected to serve approximately 1 million patients in the U.S., highlighting a substantial market opportunity, particularly given the high unmet need and limited competitive therapies.
- Upgraded Investment Rating: Goldman Sachs initiated coverage on Mobia Medical with a buy rating and set a price target of $31, implying a 130% upside from Monday's close of $13.50, reflecting analysts' confidence in the company's growth prospects.
- Strong IPO Performance: Mobia went public on Nasdaq on May 8 at an initial price of $15, and since then, its stock has risen about 15%, with a 9% increase on Tuesday following Goldman's bullish call, indicating market optimism about its future.
- Rising Stroke Incidence: With approximately 800,000 strokes occurring annually in the U.S., a figure expected to rise due to an aging population, Mobia's Vivistim system is poised to address the growing patient demand, further solidifying its market position.
See More
Five IPOs and Three SPACs Priced This Week
- HawkEye 360 IPO Performance: HawkEye 360 priced at the top of its range, raising $416 million with a market cap of $2.8 billion; despite being unprofitable, its strong revenue growth and increasing backlog indicate significant potential in the defense technology sector.
- Odyssey Therapeutics Financing: Odyssey Therapeutics priced its upsized IPO at the top of the range, raising $279 million with a market cap of $911 million; although its stock fell 9%, the development of targeted therapies for autoimmune diseases suggests robust market demand.
- Suja Life Market Challenges: Suja Life priced at the bottom of its range, raising $187 million with an $813 million market cap; despite leading in the cold-pressed juice market, a 15% decline in stock price highlights potential threats from shifting consumer preferences.
- Rare Earths Americas IPO Success: Rare Earths Americas priced at the top of its range, raising $63 million with a market cap of $399 million; focusing on heavy rare earth elements, its stock rose 23% during the week, reflecting market confidence in its growth prospects.
See More
Odyssey and Mobia Stocks Plummet After IPOs Raising Over $450M
- Odyssey IPO Performance: Odyssey Therapeutics (ODTX) raised approximately $304 million in its IPO, opening at $20, an 11% increase from its $18 offering price, but by 2 PM ET, the stock had declined to $16.49, reflecting an 8% pullback that raises concerns about its long-term growth potential.
- Mobia Stock Fluctuation: Mobia Medical (MOBI) raised $150 million in its IPO, opening at $14, down 7% from its $15 offering price, and further dropped to $11.49 by 2:10 PM ET, indicating a 23% decline, suggesting a lack of investor confidence in its market outlook.
- Market Reaction Analysis: Both companies experienced significant stock price declines post-IPO, indicating that despite raising over $450 million, the market remains cautious about the short-term performance of the biotech and MedTech sectors, which could impact future fundraising capabilities.
- Investor Confidence Challenge: The IPO performances of Odyssey and Mobia reflect a testing of investor confidence in newly listed companies, particularly in the current economic climate, which may lead to diminished interest in similar firms in the future.
See More
